Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': Navigating the minefield of drug interactions and pharmacogenomics

Mycoses

Volumn 57, Issue 9, 2014, Pages 572-576

  Trubiano, J A ^a   Paratz, E ^a   Wolf, M ^a   Teh, B W ^a   Todaro, M ^b   Thursky, K A ^a,c   Slavin, M A ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

CYP2C19; Endophthalmitis; Haematology; Miltefosine; Scedosporium prolificans; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CIMETIDINE; CYTARABINE; CYTOCHROME P450 2C19; IDARUBICIN; MILTEFOSINE; PIPERACILLIN PLUS TAZOBACTAM; TERBINAFINE; VANCOMYCIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ACUTE BIPHENOTYPIC LEUKEMIA; AGED; ARTICLE; ASPERGILLOSIS; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; ENDOPHTHALMITIS; HUMAN; MYCOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOGENOMICS; PNEUMONIA; PRIORITY JOURNAL; RETINA DETACHMENT; SCEDOSPORIUM PROLIFICANS; SCEDOSPORIUM PROLIFICANS INFECTION; ACUTE GRANULOCYTIC LEUKEMIA; COMPLICATION; DEBRIDEMENT; DRUG INTERACTION; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIOLOGY; MYCOSES; PHARMACOGENETICS; SCEDOSPORIUM;

SCEDOSPORIUM PROLIFICANS;

AGED; ANTIFUNGAL AGENTS; CIMETIDINE; CYTOCHROME P-450 CYP2C19; DEBRIDEMENT; DRUG INTERACTIONS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYCOSES; PHARMACOGENETICS; SCEDOSPORIUM; VORICONAZOLE;

EID: 84905742863     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12199     Document Type: Article

References (32)

1. Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien V. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852: 223-8.
2. Hot A, Maunoury C, Poiree S et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect 2011; 17: 409-17.
3. Vos FJ, Bleeker-Rovers CP, Oyen WJ. The use of FDG-PET/CT in patients with febrile neutropenia. Semin Nucl Med 2013; 43: 340-8.
4. Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol 2008; 46: 23-29.
5. Marin J, Sanz MA, Sanz GF et al. Disseminated Scedosporium inflatum infection in a patient with acute myeloblastic leukemia. Eur J Clin Microbiol Infect Dis 1991; 10: 759-61.
6. Rodriguez-Tudela JL, Berenguer J, Guarro J et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 2009; 47: 359-70.
7. Park WB, Kim NH, Kim KH et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55: 1080-7.
8. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
9. Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother 2012; 18: 501-7.
10. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-2.
11. Wood N, Tan K, Purkins L et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56(Suppl. 1): 56-61.
12. Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56(Suppl. 1): 51-55.
13. Moriyama B, Elinoff J, Danner RL et al. Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother 2009; 53: 1712-4.
14. Boyd NK, Zoellner CL, Swancutt MA, Bhavan KP. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections. Antimicrob Agents Chemother 2012; 56: 6001-2.
15. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58.
16. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 2010; 69: 222-30.
17. Weiss J, Ten Hoevel MM, Burhenne J et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009; 49: 196-204.
18. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 75: 587-8.
19. Ashbee HR, Gilleece MH. Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. Bone Marrow Transplant 2012; 47: 881-94.
20. Heyn K, Tredup A, Salvenmoser S, Muller FM. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005; 49: 5157-9.
21. Bocanegra R, Najvar LK, Hernandez S, McCarthy DI, Graybill JR. Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis. Antimicrob Agents Chemother 2005; 49: 5139-41.
22. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3, 378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-21.
23. Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol 2003; 41: 3981-5.
24. Widmer F, Wright LC, Obando D et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother 2006; 50: 414-21.
25. Obando D, Widmer F, Wright LC, Sorrell TC, Jolliffe KA. Synthesis, antifungal and antimicrobial activity of alkylphospholipids. Bioorg Med Chem 2007; 15: 5158-65.
26. Kesson AM, Bellemore MC, O'Mara TJ, Ellis DH, Sorrell TC. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis 2009; 48: 1257-61.
27. Biswas C, Sorrell TC, Djordjevic JT, Zuo X, Jolliffe KA, Chen SC. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens. J Antimicrob Chemother 2013; 68: 2842-6.
28. Idigoras P, Perez-Trallero E, Pineiro L et al. Dissemiantd infection and colonization by scedosporium prolificans: a review of 18 cases, 1990-1999. Clin Infect Dis 2011; 32: E158-65.
29. McKelvie PA, Wong EY, Chow LP, Hall AJ. Scedosporium endophthalmitis: two fatal disseminated cases of Scedosporium infection presenting with endopthalmitis. Clin Experiment Ophthalmol 2011; 29: 330-4.
30. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22: 111-3.
31. Vagefi MR, Kim ET, Alvarado RG, Duncan JL, Howes EL, Crawford JB. Bilateral endogenous Scedosporium prolificans endopthalmitis after lung transplantation. Am J Ophthalmol 2005; 139: 370-3.
32. Reinoso R, Carreno E, Hileeto D et al. Fatal disseminated Scedosporium prolificans infeciton initiated by opthalmic involvement in a patient with acute myeloblastic leukemia. Diagn Microbiol Infect Dis 2013; 76: 375-8.